Objective: Several observational studies suggest that medroxyprogesterone acetate (MPA) injectable contraceptives may increase a woman's risk of sexual HIV-1 acquisition. In-vitro studies are conflicting, mainly due to differences in the type of progestin studied or activation status of the primary cells. We sought to determine whether MPA increases infection of unstimulated peripheral blood mononuclear cells (PBMCs).
Introduction
There are currently over 18 million women worldwide infected with HIV-1, many of whom are of reproductive age [1] . These women require access to well tolerated and effective contraception, which prevents maternal deaths, unintended pregnancy, unsafe abortions and infant morbidity and mortality [2] . However, several observational studies have suggested that hormonal contraceptives, particularly injectable medroxyprogesterone acetate (MPA), increases a woman's susceptibility to sexual HIV-1 infection [3] [4] [5] [6] [7] . In one large prospective study in HIV-1 serodiscordant couples, MPA was associated with a two-fold (adjusted hazard ratio 2.05, 95% confidence interval 1.04-4.04) higher risk of HIV-1 acquisition than nonhormonal contraceptive methods [5] . The impact of hormonal contraceptives on HIV acquisition among women who inject drugs has received little investigative attention [8] .
MPA is different from other progestin contraceptives, as it is a derivative of progesterone, similar to the progesterone rods used in macaque simian immunodeficiency virus transmission studies, while other progestin contraceptives are mostly derivatives of testosterone [9] . Whereas all progestin contraceptives bind the progesterone receptor [10] , MPA is one of relatively few progestins that is also a partial to full agonist of the glucocorticoid receptor. Sex steroid hormones that signal via glucocorticoid receptor and progesterone receptor may influence antigen presentation and T-cell responses, and the number and function of immune cells [11] [12] [13] . MPA binds to the glucocorticoid receptor, which is expressed on peripheral mononuclear blood cells (PBMCs), with greater affinity than cortisol [14] . Thus, MPA could potentially impact susceptibility to HIV-1 infection.
Previous in-vitro studies have given mixed results concerning the influence of MPA on HIV-1 infection. However, some of these studies focused on the effect of progesterone and other progesterone receptor agonists, but not MPA [15, 16] . In addition, other studies used exogenous stimulation of primary cells prior to MPA exposure, which may not replicate normal physiologic responses. This exogenous stimulation activates CD4 þ T cells and renders them more efficient at HIV-1 infection and/or replication [17, 18] .
Hence, the purpose of this study is to determine the effect of MPA on HIV-1 infection in more clinically relevant conditions. We used freshly isolated and purified PBMCs without exogenous stimulation [19] , and concentrations of MPA similar to those measured in vivo after MPA injection to closely recapitulate susceptibility to HIV-1 infection in women using the drug [20] . We used an assay with a wide dynamic range and sensitivity to detect differences in a single round of infection. Initially, we studied nonstimulated PBMCs from male donors and later added female donors to determine whether there were sex differences.
Materials and methods

Study participants
Blood was obtained from healthy female volunteers in the follicular phase of the menstrual cycle who denied use of exogenous hormones and from healthy adult men. We selected the follicular phase of the menstrual cycle when immune defenses are purportedly high to reduce any confounding effect of the hypothesized increased susceptibility to HIV infection that occurs in the luteal phase of the menstrual cycle [21, 22] . The Johns Hopkins Institutional Review Board approved this study. All donors provided written, informed consent.
Drug dilutions
MPA (Sigma-Aldrich, St. Louis, Missouri, USA) was dissolved in dimethyl sulfoxide (DMSO; Sigma-Aldrich) at a concentration of 600 ng/ml and then diluted in phenol-red free RPMI 1640 (Gibco Laboratories, Grand Island, New York, USA) to concentrations ranging from 0.003 to 5 ng/ml. These concentrations represent physiologic serum concentrations after administration of either 150 mg MPA intramuscularly or 104 mg MPA subcutaneously. Typically, serum MPA concentration plateaus at approximately 1.0 ng/ml for about 12 weeks, and then it declines [20] . Final concentration of DMSO was less than 0.1%.
Cell cultures
Fresh PBMCs were isolated from whole blood using Ficoll (GE Healthcare Biosciences, Pittsburgh, Pennsylvania, USA) density gradient centrifugation. Previous studies demonstrated that the combination of phytohemagglutinin (PHA) and interleukin (IL)-2 can activate PBMC populations via a pathway that requires monocytes or soluble monocyte products such as IL-1 and IL-6 [23, 24] . Hence, for activation experiments, PBMCs were cultured in medium containing 0.5 mg/ml PHA and 100 U/ml of IL-2 for 72 h. Otherwise, cells were cultured in phenol-red free RPMI 1640 supplemented with 10% charcoal stripped, heat-inactivated fetal bovine serum (FBS; Gibco) and 12 mmol/l HEPES. For infections, 6 Â 10 5 PBMC or 1.5 Â 10 5 CD4 þ T cells per well were incubated with MPA for 18 h before infection in roundbottom 96-well plates at 378C in 5% CO 2 in duplicate. Negative control wells contained DMSO. In one infection experiment, cells were washed twice with PBS to remove MPA from the culture media before pseudotyped virus was added, although MPA remained in the culture media for all other infection experiments.
For experiments involving isolation of CD14 þ cells (monocytes), PBMCs were stained with CD14 À PE (phycoerythrin; Becton Dickinson, San Jose, California, USA) after incubation with Fc receptor blocker (Miltenyi, San Diego, California, USA) for 10 min at room temperature. The live CD14 þ monocyte population was separated from the CD14 À population using a FACSAria III cell sorter (Becton Dickinson). For experiments involving CD4 þ T cells, CD4 þ T cells were negatively selected from stimulated or unstimulated PBMC using the Miltenyi human CD4 þ T-cell Isolation Kit II (Gladbach, Germany) according to the manufacturer's instructions. Purity was confirmed using flow cytometry with CD3-phycoerythrin Cyanine5 (PE Cy5; Becton Dickinson) and CD4-fluorescein isothiocynate (FITC; Becton Dickinson).
Infectivity assay X4 and R5-tropic pseudoviruses were generated as previously described [25] . Briefly, HEK293T cells were cotransfected with X4 or R5 env vectors and an NL43 plasmid in which green fluorescent protein (GFP) was inserted into the env open reading frame (NL43eGFP). The envelope was provided in trans by cotransfection with a CCR5-tropic or CXCR4-tropic envelope expression vector. The pseudotyped virus particles contain functional HIV-1 Env protein and infect target cells in a physiologic, Env-dependent manner; however, the infection is limited to a single cycle because the pseudotyped virus does not express the env gene and thus the next round of replication results in nonfunctional virions. X4 or R5 pseudoviruses (50 or 100 ng p24, respectively) were added per well and infection was initiated through spinoculation at 1200g for 2 h at 308C [26] . After spinoculation, cultures were incubated at 378C for 72 h in 5% CO 2 . Cells were washed, treated with an Fc receptor blocking agent (Miltenyi) to minimize nonspecific binding and stained with labelled CD3 (PE Cy5) and CD8 (APC) antibodies on ice for 25 min in the dark. CD4 þ expression was not analysed because it is downregulated on infected cells [27, 28] ; instead, CD4 þ T cells were defined as CD3 þ CD8 À cells. After incubation, plates were washed twice with PBS, centrifuged at 335g for 10 min and fixed with 5% paraformaldehyde. Flow cytometry (BD FACSCalibur) was performed, and 100 000-200 000 events were acquired. Fluorescence emitted by the cells carrying GFP-expressing virus was quantified using CellQuest software (Becton Dickinson). To assess which cell populations were infected, we first gated on live populations of lymphocytes (R1) and monocytes and other cell populations (R2) (Fig. 1 ). The percentage of infected cells in each experimental well was divided by the percentage of infected cells in MPA-free cultures and reported as relative infection.
Entry assay X4 and R5-tropic single-cycle, pseudoviruses that incorporate the enzyme b-lactamase fused to the viral accessory gene vpr were made as previously described [29] . X4 and R5 pseudotyped viruses were used to infect 200 000 MPA-treated PBMCs. After spinoculation, viruses were left to fuse with the target T cells for 2 h at 378C. Cells were washed once and then incubated with CCF2-AM, a cell-permeating substrate (Invitrogen) for 1 hr at room temperature. About 1 mmol/l T20 was added to stop any further fusion events. Cells were washed twice and then subsequently incubated overnight in CO 2independent medium (Invitrogen) supplemented with 10% charcoal stripped FBS. CCF2 is a fluorescence resonance energy transfer (FRET) substrate that emits at 520 nm when excited by a 405 nm laser. When the substrate is cleaved by the enzyme b-lactamase, the dye emits at 447 nm. This change in emission can be monitored by flow cytometry. After 12 h, the cells were fixed with 5% paraformaldehyde and analysed on FACSCalibur. Percentage of PBMC in MPA-containing cultures that had undergone a fusion event was divided by the percentage of PBMC in MPA-free cultures to give a value for relative fusion.
Immune activation markers and HIV-1 coreceptor expression About 2 Â 10 5 PBMCs were incubated in MPA concentrations ranging from 0.003 to 3 ng/ml. Cells were washed once, treated with Fc receptor blocking agent (Miltenyi) and stained with fluorochrome-conjugated antibodies (BD Biosciences) specific for the following cell surface markers: CD3 and CD4 or CD14; CCR5 (CD195 clone 3A9:APC) or CXCR4 (CD184; APC), CD25, CD69, HLA-DR, CD38 and CD16. PHA-IL2 activated cells and DMSO-treated cells were used as positive and negative controls, respectively. Cells were incubated on ice for 25 min in the dark, washed and fixed with 5% paraformaldehyde. Percentage of CD3 þ CD4 þ or CD3 À CD14 þ cells expressing surface markers, and median fluorescence intensity (MFI), were quantified using flow cytometry within 24 h. At least 50 000 events were acquired.
Statistical analysis
Experimental replicates were averaged. Summary statistics were reported as median and interquartile range (IQR). Differences in absolute and relative infection between cells treated with varying MPA concentrations or between cell types were analysed using a nonparametric test. Significance was defined as a P value less than 0.05. Bonferroni method was used to correct for multiple comparisons in some analyses. For immunofluorescence analyses, data from MPA-treated cells were pooled and compared with no-drug controls, and weighted mean AE SEM were calculated. GraphPad Prism 6.0 (GraphPad Software, LaJolla, California, USA) was used to perform the analyses.
Results
Medroxyprogesterone acetate increases infection of unstimulated peripheral blood mononuclear cell by X4 and R5 pseudotyped HIV-1
The fraction of cells expressing GFP was measured 72 h after MPA-treated PBMCs were infected. Lymphocyte viability was more than 70% in all cultures. In unstimulated PBMCs, the maximum infection was 1.43% in CD3 þ CD8 À T cells infected with R5-tropic pseudovirus (n ¼ 21 unique donors), whereas the maximum absolute infection was 4.87% in T cells infected with X4-tropic pseudovirus (n ¼ 13 unique donors). Infection varied from donor to donor, probably due to differences in baseline activation. There were no differences in infection between male and female donors, hence the results are not stratified by sex.
Absolute infection was greater among MPA-treated T cells than among untreated cells across all MPA concentrations (0.003-3 ng/ml) using R5 pseudovirus (P < 0.003), and at concentrations 0.03 and 0.3 ng/ml using X4 pseudovirus (P < 0.005). Relative R5 and X4 infection of T cells is demonstrated in Fig. 2a manner but decreased at the highest concentration, which showed decreased cell viability. Washing MPA from PBMC cultures before spinoculation did not change the results (data not shown).
To determine the cell types infected within gates R1 and R2, we stained PBMC after infection. First, we looked for CD3 þ cells expressing GFP that were negative for CD8 and identified these as infected CD4 þ T cells (Fig. 1b, c) . We identified infected monocytes as CD3 À CD14 þ cells expressing GFP within the R2 population. Both CD4 þ T cells and CD3 À CD14 þ monocytes were found to be more susceptible to infection after pretreatment with MPA ( Fig. 2c, d) .
Relative infection of CD4 þ T cells ranged from 1.1 to two-fold higher than controls at varying MPA concentrations using R5 virus, and 1.4 to 3.6-fold higher in CD3 À CD14 þ monocytes from MPA-treated PBMC cultures than controls. There was a statistically significant increase in relative infection in MPA-treated cultures compared with no drug controls at 0.5 ng/ml for CD4 þ T cells and 0.05-5 ng/ml for CD3 À CD14 þ monocytes (P < 0.0125 for all).
Increased PBMC of CD14 þ cells. There was increased relative R5 virus infection of CD3 þ CD8 À cells in whole PBMC cultures but not after CD3 À CD14 þ cells were depleted (Fig. 3a ). In addition, there was significantly greater relative R5 virus infection in whole PBMC cultures than CD14 þ depleted PBMC cultures (P < 0.02 for all concentrations).
HIV infection of isolated CD4 R T cells decreases with medroxyprogesterone acetate treatment
In contrast to the results of unfractionated PBMC, when CD4 þ T cells were isolated by negative selection and incubated with MPA, R5 infection decreased in a doseresponse manner (Fig. 3b ).
In-vitro activation minimizes the effect of medroxyprogesterone acetate
Because activation of cells modulates coreceptor density, which, in turn, affects susceptibility to infection [30] [31] [32] , for some experiments, we activated PBMC using PHA/ IL-2 for 72 h [ Fig. 4 (n ¼ 7 and n ¼ 5 unique donors for R5 and X4, respectively)]. In stimulated PBMC, MPA infection was no different than control across varying concentrations of MPA (P > 0.5).
Medroxyprogesterone acetate mediated increase in HIV infection of peripheral blood mononuclear cell occurs postentry
It is possible that the increase in infectivity observed may be a result of MPA-induced entry of the virus into PBMC. Hence, we used a fusion assay that makes use of a b-lactamase reporter to determine whether MPA causes increased fusion of virus to target cells. We found that there are no differences in fusion of virus to MPA-treated target cells and controls ( Fig. 5 , n ¼ 4 unique donors). These data suggest that the mechanism of increased infection with MPA most likely occurs following fusion within of the viral life cycle. 
Discussion
To our knowledge, this is the first report of increased HIV-1 infection of MPA-treated, unstimulated PBMC in a dose-dependent manner that required the presence of monocytes. The results indicate that PBMCs exposed to MPA, even for 16-18 h, are more susceptible to HIV-1 infection than untreated cells. Moreover, our data clearly demonstrate that this difference in susceptibility to infection is lost when cells are exogenously stimulated. Lastly, we observed a dose-response relationship for both CD4 þ T cells and monocytes. These data provide confirmation of a biological association between MPA exposure and increased susceptibility to HIV-1 infection.
The precise molecular mechanism by which MPA increases susceptibility of PBMC to HIV-1 infection is yet to be determined. However, we eliminated several possibilities. First, increased infection was still observed when MPA was removed from the culture media by washing the cells, suggesting that MPA has an effect on the target cells rather than the virus. Second, direct quantitation of viral entry demonstrated no difference between MPA-treated PBMC and untreated control PBMC. Furthermore, immunofluorescence staining for CXCR4 and CCR5 showed no significant differences between MPA-treated PBMC and controls. Hence, our results suggest a mechanism of increased infectivity that predominantly affects postentry steps in the virus life cycle. Resting CD4 þ T cells are relatively nonpermissive for HIV-1 infection, but can be rendered permissive by various forms of T cell activation [17] . However, we did not detect significant differences between MPA-treated PBMC and controls in the expression of the activation markers CD25, CD69, CD38 and HLA-DR. Last, depletion experiments suggest that MPA's action may be dependent upon the presence of monocytes. This hypothesis is supported by the observation that CD4 þ T cells cultured alone did not show increased susceptibility to HIV-1 infection on exposure to MPA. Rather, a slight protection against HIV-1 infection was observed. This difference in susceptibility to infection suggests that CD4 þ T cells cultured alone with hormones may behave differently compared with those cultured in the presence of other cell types such as monocytes present in the PBMC fraction. This observation is important, especially in the light of recent studies of CD4 þ T cell cultures that concluded that oestrogen confers protection against HIV-1 infection [33] .
Our findings are in contrast to Vassiliadou et al. [15] , who did not find increased HIV-1 replication in progesteronetreated, PHA-stimulated PBMC. However, there are several major methodological differences. First, progesterone was used in experiments by Valissaidou et al. [15] ; this hormone is distinct from MPA. Not all progestogens are alike, and some bind different receptors, resulting in different biological effects [9, 12] . Second, in order to simulate physiologic conditions, we performed experiments with and without exogenous stimulation with PHA. Our results reveal that there are distinct differences in HIV-1 in-vitro infection between unstimulated and stimulated MPA-treated cell cultures. Last, we used a more sensitive HIV-1 infectivity assay that is able to quantify infection at the single-cell level.
Our findings are consistent with Hujbrets et al. [34] , who demonstrated in stimulated PBMC that MPA increased HIV-1 replication. However, as our data and others have shown, stimulation of primary cells alters HIV-1 infection [17, 18] . In addition, the authors suggest that MPA decreases production of interferon-gamma (IFN-g), IL-2 and tumour necrosis factor-alpha (TNF-a), which leads to the suppression of innate and adaptive mechanisms of immune control and subsequent increased susceptibility to HIV-1 infection. Although we did not measure cytokines or chemokines, this proposed mechanism contrasts other studies. For example, higher systemic inflammation and innate immune activation were independently associated with HIV-1 seroconversion in one microbicide trial [35] . Women who seroconverted had significantly higher levels of pro-inflammatory and T-cell cytokines TNF-a, IL-2, IL-7 and IL-12p70, and higher proportions of activated natural killer (NK) cells expressing HLA-DR and CD69, than women who did not seroconvert. Furthermore, decreased immune activation and cytokine production are associated with lower viremia and better outcomes in HIV-1 infection [33, 36] . The significance of these contrasting findings is unknown.
The strengths of our study include use of a simple, sensitive, quantitative and physiologically sound assay.
Second, to simulate physiologic conditions, we performed experiments without exogenous stimulation, and we demonstrated that use of exogenous stimulation can alter results. Without exogenous stimulation, we report lower levels of infection overall and greater interdonor variation than exogenous stimulation using PHA, cytokines and/or other methods of cell surface receptor engagement, which might yield higher infection and less interdonor variation. Third, experiments using unstimulated PBMCs were repeated in more than 20 individual blood donors, which increased accuracy. Last, we tested our hypothesis using both CCR5 and CXCR4 pseudotyped viruses to assess differences in viral tropism.
However, there are limitations. We chose to use PBMC as opposed to genital tract cells, thus our findings are more applicable to systemic HIV-1 infection such as injection drug use (IDU), than sexual HIV-1 infection. Although there may be phenotypic differences between peripheral and genital tract cells, there are no data demonstrating relevant functional differences. In fact, one study showed that vaginal macrophages are monocyte-like and permissive to HIV-1 replication [37] . In addition, although use of pseudotyped viruses provides a precise quantitative measurement of viral infection, it does not measure the events in the viral life cycle that occur after protein (GFP) expression. It is thus possible that there are differences in HIV-1 budding from CD4 þ T cells from MPA-treated cultures vs. controls.
The question of whether MPA increases susceptibility to HIV-1 acquisition has critical medical and public health ramifications. Over 100 million doses of MPA have been distributed worldwide, and the drug is commonly used by women of low socioeconomic status who often reside in areas of high HIV-1 prevalence [38] . Some proponents have argued that the reported associations between MPA use and increased susceptibility to sexual HIV-1 infection may be artificial and attributable to confounding factors such as behavioural factors, that is sex without condoms. Although this argument is reasonable, it is not supported by conclusive evidence and does not explain why this association has not been consistently observed in women on oral contraceptive pills [39] . Women at a high risk for sexual HIV-1 infection should be made aware that MPA does not protect against sexually transmitted diseases (STDs) including HIV, and therefore barrier methods should be used. Importantly, our results suggest that future research is needed on the potential impact of MPA on HIV acquisition among women who inject drugs. Although provocative, it is unclear whether our in-vitro findings can be extrapolated to current users of injectable MPA. Further investigation is warranted. 
